Icon of the Instituts for Quality and Efficiency in Health Care

[A22-69] Secukinumab (enthesitis-associated arthritis) – Benefit assessment according to § 35a SGB V

Last updated 17.10.2022

Project no.:
A22-69

Commission:
Commission awarded on 12.07.2022 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Muscles, bones and joints

Indication:

Alone or in combination with methotrexate for the treatment of active enthesitis-associated arthritis in patients aged 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy

Result of dossier assessment:

Added benefit not proven

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Project no. Title Status
A17-08 Secukinumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V (new scientific findings) Commission completed
A15-20 Secukinumab - Benefit assessment according to §35a Social Code Book V (dossier assessment) Commission completed
A15-53 Secukinumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V Commission completed
A20-78 Secukinumab (plaque psoriasis in children and adolescents) - Benefit assessment according to §35a Social Code Book V Commission completed
A20-79 Secukinumab (non-radiographic axial spondyloarthritis) - Benefit assessment according to §35a Social Code Book V Commission completed
A20-80 Secukinumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V Commission completed
A22-68 Secukinumab (juvenile psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V Commission completed
A23-51 Secukinumab (hidradenitis suppurativa) – Benefit assessment according to §35a Social Code Book V Commission completed

Contact

Press contact

+49 221 356850

presse@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page